ANVISA Fast-Track Approvals: Key Changes for Oncology Drugs in Brazil
This article explores the recent key changes in ANVISA's fast-track approval process for oncology drugs in Brazil, focusing on improving patient access to vital treatments.
Quick Answer
This article explores the recent key changes in ANVISA's fast-track approval process for oncology drugs in Brazil, focusing on improving patient access to vital treatments.
Key Questions
- What regulatory changes did ANVISA implement in November 2025?
- How does the reliance pathway work for oncology drug approvals in Brazil?
- What is the difference between RDC 204/2017 and RDC 997/2025?
- Which oncology drugs have recently received ANVISA approval?
- Will the 2025 regulatory reforms become permanent?
ANVISA implemented temporary regulatory reforms on November 7, 2025, through RDC 997/2025, establishing reliance pathways and grouped analysis procedures to accelerate oncology drug approvals in Brazil through December 2026.
Contents11 sections
Key Takeaways
- Regulatory foundation: RDC 997/2025, published November 7, 2025, creates temporary exceptional measures valid through December 31, 2026, to reduce ANVISA's regulatory backlog for medicines and biological products.
- Reliance pathway: The resolution implements optimized analysis procedures under IN 289/2024 and RDC 945/2024, allowing ANVISA to use assessments from FDA, EMA, and other reference regulatory authorities.
- Grouped analysis: Products sharing the same technical/clinical reports or active pharmaceutical ingredients may be analyzed collectively through Exceptional Management Plans (PGA Excepcional), streamlining evaluation of related oncology therapies.
- Priority queues: Eligible petitions are allocated to specific optimized analysis queues rather than standard chronological lines, with five sub-queues established for CADIFA, bioequivalence studies, quality, impurity qualification, and safety/efficacy.
- Strategic window: The temporary nature of these reforms creates a finite opportunity for pharmaceutical companies to secure accelerated approvals while ANVISA evaluates whether to make specific measures permanent based on 2026 performance data.
What Regulatory Changes Did ANVISA Implement in 2025?
On November 7, 2025, ANVISA's Collegiate Board (DICOL) announced a comprehensive package of structural and immediate measures to optimize regulatory queues. The centerpiece, RDC 997/2025, establishes exceptional and temporary procedures for clinical research authorizations and drug registration applications.
The resolution addresses Brazil's pharmaceutical regulatory backlog through several mechanisms. First, it creates specific queues for products qualifying under reliance procedures. Second, it enables grouped analysis of applications sharing technical characteristics. Third, it establishes exceptional management plans that may temporarily depart from strict chronological review order when justified by efficiency gains.
The measures apply to petitions protocolled through November 10, 2025, with clinical research applications eligible throughout the resolution's validity period. ANVISA estimates these reforms will normalize registration queues within one year while maintaining technical rigor.
How Does the Reliance Pathway Accelerate Approvals?
The reliance pathway (confiança regulatória) represents ANVISA's formal adoption of regulatory trust principles aligned with World Health Organization harmonization initiatives. Under IN 289/2024 and RDC 945/2024, ANVISA may accept data and assessments from reference regulatory authorities (AREE) including FDA, EMA, Health Canada, and comparable agencies. Brazil's clinical trial environment continues to evolve with these reforms.
For oncology drugs, this pathway offers significant advantages. Products already approved by FDA or EMA may qualify for optimized analysis procedures including verified screening (triagem verificada) or abbreviated analysis (análise abreviada). These procedures focus regulatory review on critical safety and efficacy aspects while accepting prior authority assessments for quality and manufacturing documentation.
The General Medicines Management (GGMED) has established five specialized sub-queues for reliance-eligible applications: CADIFA (drug information), bioequivalence studies, quality assessments, impurity qualification, and safety/efficacy reviews. Each queue processes applications in order of reliance petition entry rather than standard chronological filing.
What Is ANVISA's Historical Regulatory Framework?
ANVISA's current approach builds upon foundations established in RDC 204/2017 and RDC 205/2017, which created permanent prioritization criteria for marketing authorization applications. These 2017 resolutions established priority review for products addressing unmet medical needs, serious debilitating conditions without therapeutic alternatives, and public health emergencies.
The 2017 framework prioritized applications based on therapeutic value rather than procedural efficiency. Under RDC 204/2017, priority drugs received accelerated review timelines but still required complete domestic dossiers including Brazil-specific clinical data. The 2025 reforms fundamentally differ by accepting reliance on foreign regulatory assessments and enabling procedural optimizations independent of therapeutic priority status.
Between 2017 and 2025, ANVISA's accelerated approval pathway faced persistent challenges. Resource constraints, increasing application volumes, and requirements for local clinical data created approval lags compared with FDA and EMA timelines. The 2025 reforms directly address these structural limitations through reliance pathways and grouped analysis.
How Do Grouped Analysis Procedures Work?
RDC 997/2025 introduces Exceptional Management Plans (PGA Excepcional) enabling grouped analysis of related applications. Under Article 5, GGMED may develop plans grouping products sharing the same active pharmaceutical ingredient, identical technical/clinical reports, or common sponsoring companies.
This grouped approach offers several operational advantages. Regulatory reviewers can identify patterns across related submissions, apply consistent standards, and reduce redundant evaluation steps. For pharmaceutical companies, grouped analysis creates opportunities to coordinate submissions for product families, combination therapies, or related indications within a single regulatory framework.
The PGA Excepcional mechanism may designate analysis orders differing from strict chronology when justified by efficiency gains or backlog reduction. ANVISA has committed to publishing detailed reports on queue modifications, ensuring transparency regarding which applications receive priority treatment and the rationale for such decisions.
Which Recent Oncology Approvals Demonstrate These Pathways?
Several recent approvals illustrate ANVISA's evolving regulatory approach. Keytruda (pembrolizumab) received approval for advanced endometrial carcinoma in October 2024, expanding its indication to include combination therapy with carboplatin and paclitaxel followed by monotherapy maintenance.
This approval was based on evidence from international clinical trials, demonstrating ANVISA's growing acceptance of foreign trial data for oncology indications. The endometrial carcinoma indication addressed an unmet medical need in Brazil, where approximately 7,840 new cases are diagnosed annually according to Brazilian National Cancer Institute (INCA) estimates.
| Drug | Indication | Approval Date | Category |
|---|---|---|---|
| Keytruda (pembrolizumab) | Advanced endometrial carcinoma | October 2024 | New indication |
| Enhertu (trastuzumab deruxtecan) | HER2-positive breast cancer | 2024 | New indication |
| Opdivo (nivolumab) | Multiple oncology indications | Ongoing | Biological product |
What Are the Strategic Implications for Drug Developers?
The 2025 reforms create distinct strategic considerations for pharmaceutical companies seeking Brazilian market access. Companies with existing FDA or EMA approvals can use reliance pathways to speed up ANVISA reviews without conducting additional Brazil-specific trials. This advantage is particularly significant for multinational companies with established global clinical programs.
Companies developing related oncology products should consider coordinating submission timelines to maximize grouped analysis opportunities. Applications sharing active ingredients, mechanisms of action, or sponsor organizations may qualify for PGA Excepcional treatment, potentially reducing aggregate review timelines.
The temporary nature of RDC 997/2025—valid only through December 2026—creates urgency for companies with near-term filing plans. Applications protocolled after November 10, 2025, generally do not qualify for the exceptional measures, though clinical research authorizations remain eligible throughout the resolution's validity period.
How Will These Reforms Affect Patient Access?
The regulatory changes directly address patient access delays for innovative oncology therapies. Brazil represents Latin America's largest pharmaceutical market, and historical ANVISA approval lags have delayed patient access to therapies available in North America and Europe. The reliance pathway narrows this gap by accepting FDA and EMA assessments rather than requiring duplicative domestic reviews.
The reforms may also intensify market competition. Faster approval timelines reduce barriers to entry for innovative therapies, potentially increasing treatment options and creating pricing pressure. For patients with limited therapeutic alternatives, accelerated access to immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies may improve outcomes.
Brazil's regulatory leadership may influence regional practices. As the largest pharmaceutical market in Latin America, ANVISA policies often inform regulatory approaches in neighboring countries. Successful implementation of reliance pathways and grouped analysis could spark similar reforms throughout the region, expanding patient access beyond Brazil. Companies should monitor regulatory changes as they plan their Latin America market entry strategies.
Frequently Asked Questions
What regulatory changes did ANVISA implement in November 2025?
ANVISA published RDC 997/2025 on November 7, 2025, establishing temporary measures through December 31, 2026. The resolution creates reliance-based analysis pathways for products already approved by reference regulatory authorities (FDA, EMA), implements grouped analysis for products sharing technical/clinical reports, establishes Exceptional Management Plans (PGA Excepcional) for backlog reduction, and creates specific priority queues for synthetic drugs and biological products meeting reliance criteria under IN 289/2024.
How does the reliance pathway work for oncology drug approvals in Brazil?
The reliance pathway (confiança regulatória) allows ANVISA to use assessments conducted by reference regulatory authorities like FDA and EMA. Under IN 289/2024 and RDC 945/2024, oncology drugs approved by these agencies may qualify for optimized analysis procedures, including verified screening, abbreviated analysis, or direct reliance on foreign authority decisions. Products meeting criteria are allocated to specific priority queues rather than standard chronological review lines, significantly reducing approval timelines.
What is the difference between RDC 204/2017 and RDC 997/2025?
RDC 204/2017 established permanent prioritization criteria for drugs addressing unmet medical needs, serious debilitating conditions, and public health emergencies. RDC 997/2025 introduced temporary exceptional measures valid through December 2026 specifically targeting backlog reduction. While RDC 204/2017 focuses on priority designation based on therapeutic value, RDC 997/2025 implements procedural optimizations including reliance pathways, grouped analysis, and exceptional management plans that temporarily modify standard review sequences.
Which oncology drugs have recently received ANVISA approval?
Keytruda (pembrolizumab) received approval for advanced or recurrent endometrial carcinoma in combination with carboplatin and paclitaxel in October 2024. This indication was based on clinical evidence from international trials. Several other immune checkpoint inhibitors and targeted therapies have been approved under ANVISA's accelerated pathways, with specific approvals documented in ANVISA's public database of new medicines and indications.
Will the 2025 regulatory reforms become permanent?
The measures in RDC 997/2025 are explicitly temporary, valid only until December 31, 2026. ANVISA will monitor outcomes through a dedicated oversight committee during this period. If the reforms demonstrate success in reducing backlogs while maintaining safety standards, ANVISA may consider making specific provisions permanent through new resolutions. Conversely, if unintended consequences emerge, the measures may be modified or discontinued. The temporary structure allows for adaptive governance based on real-world performance data.
Related Coverage
- ANVISA Regulatory Changes Brazil: Impact on Clinical Trial Landscape
- ANVISA Approves Enhertu for HER2-Positive Breast Cancer in Brazil
- NovaPharmaNews Regulatory Monitoring Center
Primary Sources
- ANVISA. ANVISA announces structural and immediate measures to optimize queues. News release, November 7, 2025.
- ANVISA. Medicines area adopts procedures to comply with RDC 997/2025. November 14, 2025.
- ANVISA. Questions and Answers on RDC 997/2025. Official guidance, updated December 22, 2025.
- ANVISA. RDC No. 204 of December 27, 2017. Prioritization of marketing authorization requests.
- ANVISA. RDC No. 205 of December 27, 2017. Prioritization for biological products.
- ANVISA. Keytruda (pembrolizumab): new indication approval. October 29, 2024.
- ANVISA. IN No. 289 of March 20, 2024. Optimized analysis procedure for reliance.
- ANVISA. RDC No. 945 of November 29, 2024. Reliance procedures for clinical research.
This article follows our editorial standards. Report a correction via editorial contact.
Continue Your Research
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…